Recent advancements in gene editing, particularly CRISPR-Cas9, have transformed genetic research and therapy development. Our research focuses on enhancing the precision and efficiency of CRISPR-Cas system, reducing off-target effects, and exploring its applications in treating genetic disorders. Our key achievement is high-fidelity base editor variants that minimizes unintended mutations, improving the safety of gene-editing therapies. We’ve also pioneered in vivo gene correction in animal models, successfully targeting diseases like Duchenne muscular dystrophy. These breakthroughs advance our understanding of gene-editing mechanisms and bring us closer to clinical applications. Moving forward, we’re focused on optimizing delivery systems and ensuring these therapies are scalable and accessible, aiming to provide safe and effective treatments for genetic disorders.